RJA
DGX icon

Raymond James & Associates’s Quest Diagnostics DGX Stock Holding History

Raymond James & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$21.9M Buy
140,982
+14,899
+12% +$2.23M 0.01% 767
2024
Q2 		$17.3M Sell
126,083
-46,602
-27% -$6.38M 0.01% 852
2024
Q1 		$23M Buy
172,685
+24,434
+16% +$3.17M 0.02% 713
2023
Q4 		$20.4M Buy
148,251
+75,315
+103% +$9.9M 0.02% 735
2023
Q3 		$8.89M Buy
72,936
+182
+0.3% +$24.2K 0.01% 1104
2023
Q2 		$10.2M Sell
72,754
-967
-1% -$133K 0.01% 1039
2023
Q1 		$10.4M Sell
73,721
-10,042
-12% -$1.44M 0.01% 998
2022
Q4 		$13.1M Buy
83,763
+4,615
+6% +$663K 0.01% 858
2022
Q3 		$9.71M Buy
79,148
+3,190
+4% +$420K 0.01% 992
2022
Q2 		$10.1M Buy
75,958
+2,389
+3% +$326K 0.01% 974
2022
Q1 		$10.1M Sell
73,569
-6,380
-8% -$889K 0.01% 1063
2021
Q4 		$13.8M Sell
79,949
-45,154
-36% -$6.87M 0.01% 927
2021
Q3 		$18.2M Sell
125,103
-22,516
-15% -$3.29M 0.02% 763
2021
Q2 		$19.5M Sell
147,619
-19,412
-12% -$2.54M 0.02% 729
2021
Q1 		$21.4M Sell
167,031
-3,863
-2% -$476K 0.02% 642
2020
Q4 		$20.4M Sell
170,894
-36,704
-18% -$4.47M 0.02% 612
2020
Q3 		$23.8M Buy
207,598
+14,913
+8% +$1.76M 0.03% 474
2020
Q2 		$22M Buy
192,685
+8,149
+4% +$864K 0.03% 482
2020
Q1 		$14.8M Buy
184,536
+110,926
+151% +$11.5M 0.02% 570
2019
Q4 		$7.86M Sell
73,610
-29,177
-28% -$3.04M 0.01% 1000
2019
Q3 		$11M Sell
102,787
-22,050
-18% -$2.26M 0.02% 821
2019
Q2 		$12.7M Buy
124,837
+15,645
+14% +$1.5M 0.02% 738
2019
Q1 		$9.82M Buy
109,192
+69,918
+178% +$6.06M 0.01% 834
2018
Q4 		$3.27M Buy
39,274
+12,214
+45% +$1.15M 0.01% 1338
2018
Q3 		$2.92M Sell
27,060
-358
-1% -$39.3K ﹤0.01% 1566
2018
Q2 		$3.01M Buy
27,418
+2,063
+8% +$215K 0.01% 1501
2018
Q1 		$2.54M Sell
25,355
-4,522
-15% -$463K ﹤0.01% 1560
2017
Q4 		$2.94M Sell
29,877
-12,387
-29% -$1.17M 0.01% 1437
2017
Q3 		$3.96M Sell
42,264
-366
-0.9% -$38.9K 0.01% 1205
2017
Q2 		$4.74M Buy
42,630
+504
+1% +$53.3K 0.01% 1050
2017
Q1 		$4.14M Sell
42,126
-24,760
-37% -$2.36M 0.01% 1112
2016
Q4 		$6.15M Buy
66,886
+860
+1% +$74.1K 0.02% 881
2016
Q3 		$5.59M Sell
66,026
-468,873
-88% -$39.4M 0.02% 891
2016
Q2 		$43.5M Buy
534,899
+22,367
+4% +$1.7M 0.14% 165
2016
Q1 		$36.6M Sell
512,532
-85,575
-14% -$5.74M 0.12% 174
2015
Q4 		$42.5M Buy
598,107
+3,582
+0.6% +$241K 0.15% 144
2015
Q3 		$36.5M Buy
594,525
+10,091
+2% +$705K 0.15% 145
2015
Q2 		$42.4M Buy
584,434
+79,822
+16% +$5.89M 0.16% 130
2015
Q1 		$38.8M Buy
504,612
+27,841
+6% +$1.99M 0.17% 120
2014
Q4 		$32M Buy
476,771
+13,511
+3% +$853K 0.16% 126
2014
Q3 		$28.1M Buy
463,260
+43,293
+10% +$2.67M 0.16% 121
2014
Q2 		$24.6M Buy
419,967
+126,949
+43% +$7.43M 0.15% 133
2014
Q1 		$17M Buy
293,018
+273,915
+1,434% +$14.7M 0.12% 195
2013
Q4 		$1.02M Buy
19,103
+990
+5% +$58.7K 0.01% 1317
2013
Q3 		$1.12M Buy
+18,113
New +$1.08M 0.01% 1193

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Raymond James & Associates's DGX Position: Q3 2024 in Review

Raymond James & Associates increased its Quest Diagnostics (DGX) stake by 12% in Q3 2024, buying an estimated $2.23M and bringing the position to 140,982 shares worth $21.9M. The position accounts for 0.01% of the portfolio, ranked #767.

Raymond James & Associates first reported a position in DGX in Q3 2013 and has held it in 45 quarters since. The position peaked at $43.5M in Q2 2016. 846 funds tracked by Wall St. Rank hold DGX as of Q3 2024.

  • Raymond James & Associates held 140,982 shares of Quest Diagnostics worth $21.9M as of Q3 2024.
  • Raymond James & Associates bought 14,899 Quest Diagnostics shares in Q3 2024, an estimated $2.23M.
  • Quest Diagnostics made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #767 holding.
  • Raymond James & Associates first reported a position in Quest Diagnostics in Q3 2013 and has held it in 45 quarters since.
  • Raymond James & Associates's Quest Diagnostics position peaked at $43.5M in Q2 2016.
  • 846 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.